In This Issue

A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors Page 1101–1108 Pancreatic neuroendocrine tumors (PanNET) are a rare but deadly form of cancer that are poorly understood. In this study, Takikawa and Ohki focus on PHLDA3, a novel tumor suppressor gene that represses the activity of Akt. They suggest that progression of PanNET occurs through inactivation of PHLDA3, and discuss the putative relationship between the efficacy of everolimus, a drug that works to extend the lives of those individuals with PanNETs, and inactivation of the PHLDA3 gene in PanNET. They also describe their previous results, which have shown frequent loss of heterozygosity and increased DNA methylation at the PHLDA3 gene in PanNET samples. Finally, they speculate that more extensive investigation of PHLDA3 might reveal further information important to a more accurate diagnosis of PanNET. doi:10.1111/cas.13235